San Diego, CA, United States of America

Lionella Borozdina-Birch

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lionella Borozdina-Birch: Innovator in Antibody Discovery

Introduction

Lionella Borozdina-Birch is a prominent inventor based in San Diego, CA (US). She has made significant contributions to the field of antibody discovery, particularly through her innovative work in combinatorial synthetic Fab libraries.

Latest Patents

Lionella holds 1 patent that is focused on combinatorial synthetic Fab libraries displayed on a phage pIX protein. This patent describes and claims libraries built on scaffolds representing the most frequently used genes in human antibodies. These libraries were diversified to mirror the variability of natural antibodies. After selection using a diverse panel of proteins, numerous specific and high-affinity Fabs were isolated. Through a process called in-line maturation, the affinity of some antibodies was improved up to one hundred-fold, yielding low pM binders suitable for in vivo use. This work demonstrates the feasibility of displaying complex Fab libraries as pIX-fusion proteins for antibody discovery and lays the foundations for studies on the structure-function relationship of antibodies.

Career Highlights

Lionella is currently employed at Janssen Biotech, Inc., where she continues to advance her research in antibody technology. Her work has been instrumental in developing new methodologies for antibody discovery, which have significant implications for therapeutic applications.

Collaborations

Lionella collaborates with esteemed colleagues, including Ping Tsui and Lei Shi, who contribute to her research endeavors and enhance the innovative environment at Janssen Biotech, Inc.

Conclusion

Lionella Borozdina-Birch is a trailblazer in the field of antibody discovery, with her innovative approaches paving the way for future advancements in therapeutic applications. Her contributions are vital to the ongoing evolution of antibody technology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…